Second Sight Medical Products (NSDQ:EYES) and Nano Precision Medical agreed to a merger deal that will result in a focus on drug-device medical implants. The two companies entered into a definitive agreement under which privately held Nano Precision Medical (NPM) will merge with a wholly-owned subsidiary of Second Sight in an all-stock transaction, with NPM […]
Second Sight
MedTech 100 roundup: Nearing new highs once again
Having hit a downturn as the summer neared, the medtech industry is now consistently on the rise as June comes to a close. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 25) at 113.42 points, producing a 2.5% rise from the 110.64-point mark set […]
Second Sight Medical plans to raise $50 million from public offering
Second Sight Medical Products announced that it plans to offer shares of its common stock in a public offering worth $50 million. Los Angeles–based Second Sight priced the underwritten public offering of 10 million shares of common stock at a public offering price of $5 per share to yield gross proceeds of $50 million, according […]
MedTech 100 roundup: Industry roars back
In the blink of an eye, the medtech industry exited its spring slump and neared its all-time best performance levels. MassDevice‘s MedTech 100 Index offered signs of a rebound last week and has built on that momentum, registering a final tally of 109.39 points on April 9. That represents a 2.9% increase from the 106.26-point mark […]
Second Sight, Pixium Vision merger plans are over
Second Sight Medical notified Pixium that it decided to unilaterally terminate a memorandum of understanding (MOU) ahead of a planned merger. In a news release, Pixium said the $27.9 million private placement recently announced and closed by Second Sight was “not only explicitly prohibited under the terms of the [MOU] entered into by the companies […]
Second Sight names acting CEO
Second Sight Medical (NSDQ:EYES) announced today that it has named a new acting chief executive officer. Los Angeles-based Second Sight said in a news release that Scott Dunbar has been named by its board of directors to replace Matthew Pfeffer as acting CEO. Under Nasdaq rules, an independent director may temporarily be named acting CEO […]
MedTech 100 roundup: Slight rise for the industry
While medtech’s performance still isn’t mirroring the beginning of 2021, the industry is showing signs of life with a small improvement last week. The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the […]
DTW Podcast – CEO MacMillan on how COVID-19 strengthened Hologic
Hologic CEO Steve MacMillan says in early March 2020 he didn’t appreciate how COVID-19 would change the world forever. But the diagnostics company quickly rose to the challenge, becoming one of the surer suppliers of diagnostic tests needed to chart the coronavirus’s severity. In this DeviceTalks Weekly podcast, MacMillan shares how Hologic pivoted to meet […]
Second Sight’s merger with Pixium Vision may fall through
Second Sight‘s plans to raise $27.9 million from a private placement appear to have generated conflict with its would-be owner Pixium Vision. Pixium informed Second Sight (NSDQ: EYES) yesterday that the private placement would breach the memorandum of understanding the two companies reached in early January, according to a Second Sight filing with the SEC. […]
Second Sight gains FDA nod for retinal system that may never be produced
Second Sight Medical (NSDQ: EYES) today announced that the FDA has approved its Argus 2s retinal prosthesis system, but questions remain about whether it will ever be manufactured. The past year has been tough for Second Sight. The company announced in March 2020 that it would wind down its operations amid the financial shock of […]
Second Sight facing Nasdaq delisting
Second Sight Medical (NSDQ:EYES) announced that it received a letter from the Nasdaq market confirming that it may face delisting. The Sylmar, Calif.-based developer and manufacturer of implantable visual prosthetics for blind individuals received the letter confirming that its common stock had closed below the $1 per share minimum required for continued listing for 30 consecutive […]
